AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-37. (Cancelled)

38. (Previously Presented) A method of forming a compound according to Formula I:



I

the method comprising the steps of

contacting an aryl halide of the formula:



with at least one molar equivalent of a organozinc reagent, RZnY, and at least a catalytic amount of a palladium catalyst to form a C-C bond by a palladium mediated cross-coupling reaction; and

contacting the product of the cross-coupling reaction with chloroformamidine under dry-fusion conditions to form a compound according to Formula I, wherein

R is a benzyl residue of the formula $-CH_2C_6H_{5-i}(R_A)_i$;

R_A is independently selected at each occurrence of R_A from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{1-6}alkoxy, chloro, fluoro, C_{1-4}fluoroalkyl, amino, mono and di(C_{1-6}alkyl)amino, nitrile, optionally substituted aryloxy, optionally substituted heteroaryloxy, C_{1-6}alkylthio, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aryl acetoxy or optionally substituted heteroaryl acetoxy; or

or

two adjacent R_A groups taken in combination form a group of the formula:

 which may be optionally substituted;

R^3 is hydrogen; and

i is 0, 1, 2, or 3;

Y is Cl, Br, I, or triflate.

39. (Previously presented) A compound according to Formula I:



I

wherein:

R_A is independently selected at each occurrence of R_A from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, chloro, fluoro, C_{1-4}fluoroalkyl, amino, mono and di(C_{1-6}alkyl)amino, and nitrile; or

two adjacent R_A groups taken in combination form a group of the formula:

 which may be optionally substituted;

R^3 is hydrogen; and

i is an integer from 0 to about 5.

40. (Cancelled)

41. (Previously presented) A compound of claim 39 wherein R_A is independently selected at each occurrence of R_A from the group consisting of hydrogen, chloro, and fluoro; or

two adjacent R_A groups taken in combination form a group of the formula:


;

R^3 is hydrogen; and

i is an integer from 0 to about 3.

42. (Previously presented) A compound of claim 39 according to Formula I-A:



I-A

wherein

two adjacent R_A groups taken in combination form a group of the formula:


; and

i is 2 .

43. (Previously presented) A pharmaceutical composition comprising a compound of any one of claims 39, 41, or 42 and a pharmaceutically acceptable carrier.

44. (Currently amended) A method for treating a mammal suffering from ~~or susceptible to~~ a *Pneumocystis carinii* infection or a *Toxoplasma gondii* infection, comprising administering to the mammal an effective amount of a pharmaceutical composition of claim 43.

45. (Original) A method of claim 44 wherein the mammal is immuno-compromised.

46. (Previously presented) The method of claim 44, wherein the mammal is HIV-positive.

47. (Currently amended) The method of ~~any~~ claim 44, wherein the mammal is suffering from an acquired immune deficiency disorder.

48. (Original) The method of claim 44, wherein the mammal is suffering from an autoimmune disorder or disease.

49. (Currently amended) The method of claim 44, wherein the mammal ~~has a parasitic~~ is suffering from *Toxoplasma gondii* infection.

50-54. (Cancelled).

55. (Previously Presented) The method of claim 44, wherein the mammal is a human.

56. (New) The method of claim 44, wherein the mammal is suffering from *Pneumocystis carinii* infection.